Table 1.

Combined therapeutic outcomes of cis mAb treatments in ssTBI mice or rmTBI mice regimens

TBI-related outcomes	Experimental tests	Treatment regimen (as used in figures)	No of total mice used	No of mice each group	Pathological and functional outcomes (fold ± SD)				Cohen’s d* or z -score effect size**	p -value
					Combined IgG/Sham		Combined Cis mAb/ Sham	Cis mAb combined effect size
Selected pathological outcomes
Cis P-tau	Cis P-tau (cortex)	5a; 4a; 7a	39	3−4	100.7 ± 0.28	11.3 ± 0.25		8.91 ± 0.36	5.99	≤0.0001
	Cis P-tau (hippo.)	5a; 4a; 7a	39	3−4	67.8 ± 0.88	5.87 ± 0.19		11.5 ± 0.91	1.98	≤0.0001
Trans P-tau	Trans P-Tau (cortex)	5a; 4a; 7a	39	3−4	1.00 ± 0.22	1.00 ± 0.21		1.00 ± 0.23	0.02	>0.05
	Trans P-Tau (hippo.)	5a; 4a; 7a	39	3−4	1.04 ± 0.24	1.03 ± 0.26		1.01 ± 0.21	0.03	>0.05
Axonal injury	Gallyas silver (cortex)	5a; 4a; 7a	39	3−4	20.8 ± 6.51	1.66 ± 0.58		12.5 ± 6.51	2.26	≤0.0001
	Gallyas silver (hippo.)	5a; 4a; 7a	39	3−4	15.2 ± 4.65	1.46 ± 0.56		10.5 ± 4.67	2.21	≤0.0001
Other tau pathology	T22 (cortex)	5a; 4a; 7a	39	3−4	81.8 ± 0.81	8.98 ± 0.22		9.12 ± 0.83	2.09	≤0.0001
	T22 (hippocampus)	5a; 4a; 7a	39	3−4	64.4 ± 0.85	5.85 ± 0.21		11.0 ± 0.87	1.93	≤0.001
	AT8 (cortex)	5a; 4a; 7a	39	3−4	69.0 ± 0.84	12.3 ± 0.27		5.63 ± 0.89	1.75	≤0.0001
	AT8 (hippocampus)	5a; 4a; 7a	39	3−4	63.8 ± 0.81	7.16 ± 0.22		8.91 ± 0.87	1.85	≤0.0002
	AT100 (cortex)	5a; 4a; 7a	39	3−4	59.8 ± 0.84	7.39 ± 0.22		8.08 ± 0.86	1.71	≤0.0001
	AT100 (hippocampus)	5a; 4a; 7a	39	3−4	60.2 ± 0.80	6.56 ± 0.21		9.18 ± 0.81	1.86	≤0.0003
APP accumulation	APP (cortex)	5a; 4a; 7a	39	3−4	3.82 ± 0.43	1.39 ± 0.19		2.74 ± 0.46	2.09	≤0.0001
	APP (hippocampus)	5a; 4a; 7a	39	3−4	2.59 ± 0.46	1.12 ± 0.12		2.30 ± 0.45	1.47	≤0.006
Neuron inflammation	GFAP (cortex)	5a; 4a; 7a	39	3−4	1.62 ± 0.13	1.06 ± 0.03		1.52 ± 0.14	1.68	≤0.0005
	GFAP (hippocampus)	5a; 4a; 7a	39	3−4	1.42 ± 0.11	1.03 ± 0.02		1.37 ± 0.11	1.51	≤0.001
Selected functional outcomes
Sensorimotor coordination defects	Ledge test	4a, b; 5a; 6a, b; 7a	99	5−9	2.92 ± 0.38	1.06 ± 0.19		2.74 ± 0.49	0.64**	≤0.0001
	String suspension	4a, b; 5a; 6a, b; 7a	99	5−9	3.32 ± 0.66	1.00 ± 0.24		3.34 ± 0.81	0.56**	≤0.0001
	Accelerating rotarod	7a	27	9	1.22 ± 0.05	0.90 ± 0.03		1.35 ± 0.04	1.22	≤0.03
Cognitive loss	Novel location recog.	7a	27	9	1.27 ± 0.05	0.91 ± 0.03		1.38 ± 0.05	1.21	≤0.03
Urinary control	Voiding pattern	5a; 7a	42	5-9	1.45 ± 0.09	0.93 ± 0.06		1.56 ± 0.10	0.55**	≤0.002

*Cohen d is classified as small (d = 0.2), medium (d = 0.5), large (d = 0.8), very large (d = 1.2), or huge (d = 2.0). **z-score is a nonparametric alternative to Cohen’s d